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Abstract
A variety of mouse models have been developed that express mutant huntingtin (mHTT)
leading to aggregates and inclusions that model the molecular pathology observed in Hun-
tington’s disease. Here we show that although homozygous HdhQ150 knock-in mice devel-
oped motor impairments (rotarod, locomotor activity, grip strength) by 36 weeks of age,
cognitive dysfunction (swimming T maze, fear conditioning, odor discrimination, social inter-
action) was not evident by 94 weeks. Concomitant to behavioral assessments, T2-weighted
MRI volume measurements indicated a slower striatal growth with a significant difference
between wild type (WT) and HdhQ150 mice being present even at 15 weeks. Indeed, MRI
indicated significant volumetric changes prior to the emergence of the “clinical horizon” of
motor impairments at 36 weeks of age. A striatal decrease of 27% was observed over 94
weeks with cortex (12%) and hippocampus (21%) also indicating significant atrophy. A
hypothesis-free analysis using tensor-based morphometry highlighted further regions
undergoing atrophy by contrasting brain growth and regional neurodegeneration. Histology
revealed the widespread presence of mHTT aggregates and cellular inclusions. However,
there was little evidence of correlations between these outcome measures, potentially indi-
cating that other factors are important in the causal cascade linking the molecular pathology
to the emergence of behavioral impairments. In conclusion, the HdhQ150 mouse model rep-
licates many aspects of the human condition, including an extended pre-manifest period
prior to the emergence of motor impairments.
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Introduction
The cause of Huntington’s disease (HD) has been identified as the abnormal expansion of a
CAG repeat in exon 1 of the huntingtin gene (HTT), that is transmitted in an autosomal domi-
nant fashion [1]. This CAG expansion encodes a polyglutamine tract in the huntingtin protein
(HTT), that is prone to aggregate and eventually manifests in neurodegeneration [2]. Neverthe-
less, the causal chain between the HD mutation and the development of disease signs remains
poorly understood [3]. By its nature, HD is a variable disease and this, coupled with the scarcity
of diseased tissue during the early stages, impede efforts to link brain atrophy and motor/behav-
ioral dysfunction to a molecular pathology [4]. Pre-manifestation markers of the condition (i.e.
biological changes that occur prior to symptom-based diagnosis) have been identified as subtle
brain changes on magnetic resonance images (MRI) that are predictive of disease burden [5–8].
Rodent models of HD provide an excellent experimental system to thoroughly investigate these
MRI-based biomarkers and associate these with cytoarchitectural and molecular changes in a
controlled fashion [9].
Transgenic mouse models include the R6 [10] and N171Q82 [11] lines that express N-ter-
minal fragments of HTT, as well as the YAC128 [12] and BACHD [13] lines that express a
mutant version of the full-length protein as artificial chromosomes. The genetic basis of HD is
more precisely recapitulated in the knock-in models, which possess an elongated CAG repeat
that has been inserted into mouse Htt, or in which exon 1 of mouse Htt has been replaced with a
mutant version of human exon 1 HTTwith an expanded CAG repeat [14]. The HdhQ150 knock-
in model contains a highly expanded CAG repeat in the mouse Htt gene of a comparable length
to that present in the R6/2 mice [15]. The model develops a more slowly progressing phenotype,
which is advantageous for capturing early pre-manifest events [16]. It exhibits clear HD-like pro-
gressive behavioral phenotypes, HTT-positive nuclear and cytoplasmic inclusions and abnormal
cytopathology [15–17]. Interestingly, the late-stage phenotypes of R6/2 mice at 12–14 weeks and
HdhQ150 mice at 90 weeks of age are highly comparable [18–24]. The R6/2 mice are a model for
the incomplete splicing of the HTT gene that occurs in all full-length mouse models of HD result-
ing in a small exon 1 –intron 1 polyadenylated mRNA that encodes and exon 1 HTT protein [25].
Although there is an extensive description of the molecular pathology in the HdhQ150 mice
[18, 20, 26, 27], only a few studies have investigated the behavioral phenotypes [16, 26, 28, 29]
or tissue changes by MRI [28]. To provide a link between molecular pathology with behavioral
performance, as well as structural brain changes, a correlational analysis in the same cohort of
animals is required, as we have previously described for the N-terminal fragment models R6/2
[30] and R6/1 [31]. To maintain face validity of the correlations between mouse models and
the human condition, outcome measures in models should provide information that is rele-
vant to the human disease [9, 32]. As HD affects the cognitive and motor abilities of patients,
behavioral tasks encompassing motor, cognitive and emotional abilities should be evaluated
longitudinally in the same animals to determine if these undergo progressive changes. To
determine changes in brain structure over time, similar to human patients, MRI can be used to
non-invasively visualize brain anatomy. Using sophisticated image analysis, it is possible to
compare subtle sub-regional changes between experiment groups, but also over time [31, 33–
35]. Based on these assessments, it is therefore possible to determine if subtle anatomical
changes precede the clinical horizon at which clinical signs are diagnosed as HD [36].
Thorough characterizations of the pathological transition are essential for establishing a
causal relationship between molecular pathology, tissue changes and resulting behavioral
impairments. Here, we describe the longitudinal assessment (94 weeks / 2 years) and the emer-
gence of behavioral dysfunctions on cognitive, motor and emotional tasks with concomitant
measurements of brain atrophy by MRI, as well as post-mortem histopathological analyses.
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Correlational analyses of time course changes in these measurements were performed to indi-
cate potential links between molecular pathology, tissue atrophy and behavioral performance,
as well as an indication to pre-manifest MRI-based biomarkers.
Methods
Ethical statement
All procedures were performance in accordance with the ethical review procedures of King’s
College London and carried out according to the Animals (Scientific Procedures) Act 1986
under the Home Office License (70/6445).
Experimental design
Wild type (WT) and HdhQ150 mice of both genders were included in a longitudinal study that
repeatedly evaluated behavioral and tissue changes from 9 until 94 weeks of age when animals
were perfusion fixed for post-mortem histopathological evaluations (Fig 1A). Motor-related
behaviors consisted of grip strength, locomotor activity in an open-field, and rotarod testing.
Non-motor-related behaviors entailed learning in a swimming T-maze; fear conditioning, odor
discrimination, and social interaction. Concomitant to these evaluations, T2-weighted MR
images were acquired to measure anatomical differences, with histological analyses determining
neuronal loss and the presence of mHTT inclusions in the striatum and cortex at the end of the
Fig 1. Experimental design and body weight measures. (A) Full experimental design from 8 to 94 weeks
of age. In vivo MRI was taken, serially, at 8, 15, 23, 36, 52, 81 and 94 weeks. Behavior was assessed
throughout the study at the weeks specified: GS = grip strength; OD = odor discrimination; SI = social
interaction; FC = fear conditioning; SM = swimming T-maze; OF = behaviors in an open field; RR = rotarod.
Body weight change in WT and HdhQ150 male (B) and female (C) mice over time. All data presented as
means ± SEM; *p < .05, **p < .01, ***p < .001.
doi:10.1371/journal.pone.0168556.g001
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study. All procedures (behavioral, MRI and histological) were conducted on the same, single
cohort of animals.
Animals
Homozygous HdhQ150 mice were obtained through crossing heterozygous HdHQ150 CBA/Ca
and C57Bl/6J lines, as previously described in detail [18]. Mice were genotyped and the CAG
repeat size was measured [21]. The CAG repeat lengths for both alleles were 161.9 (± 5.1) and
182.42 (± 9.81). CAG repeats did not significantly differ between male and female HdhQ150
mice. Littermates were divided into four groups: male wild-type (WT, n = 8); female WT (n = 9);
male HdhQ150 (n = 9); female HdhQ150 (n = 10). For exact subject numbers included at each
stage of the study see S1 Table.
All mice were housed under standard animal laboratory conditions with room temperature
maintained at 21˚C (±1) and kept on 12h light:dark cycle automatically. Cages had standard
environmental enrichment (bedding and play tube). Standard chow diet and tap water were
available ad libitum. Mice were group-housed according to gender, but genotypes were mixed
within the cages. Body weight was measured monthly, as was body temperature, measured
through an infra-red temperature reader (ThermoScan Instant Thermometer, Braun), repro-
ducibly positioned under the thorax.
Behavioral tests
Rotarod. Rotarod assesses motor coordination and integration, commonly used to evalu-
ate motor impairment in animal models of HD [37]. A previous study has shown that change
in rotarod performance is a relatively late event in homozygous HdhQ150 mice, detectable at
18 months of age only [18]. Thus, motor coordination was tested on an accelerating rotarod at
39, 55 and 78 weeks of age, using a previously described protocol [30, 31]. In brief, mice were
individually placed on an accelerating, rotating beam (4–40 rpm) for a maximum of 300 sec.
Latency to fall from the beam (sec) was recorded as a measure of motor performance. Mice
were exposed to three trials per day for four days (day 1 behavior was considered habituation
to the test and the data was subsequently discarded). The whole apparatus was thoroughly
cleaned with 70% industrial methylated spirit (IMS) between trials.
Open field. To account for locomotor activity, general ambulation was probed in an open-
field arena at 16, 26, 38, 53, 79 and 93 weeks of age. As previously described [30, 31], the test
began 2 h into the mouse’s dark cycle, conducted under red-light conditions. Mice were habitu-
ated to the test room conditions for 2 h, then individually placed into plain, featureless white are-
nas (50 x 50 x 50 cm, Engineering & Design Plastics Ltd., Cambridge, UK) for 30 min. Behavior
was videotaped via a camera positioned above the apparatus. Activity (distance moved, cm) was
later tracked and analyzed using EthoVision 7XT software (Noldus, Netherlands). Arenas were
thoroughly cleaned with 70% IMS between trials.
Grip strength. Fine motor behavior and strength in digits has been demonstrated to be
associated with disease burden and potentially provides a pre-manifest sign of the clinical hori-
zon [38]. Grip strength capacity was assessed at 9, 16, 26, 38, 53, 79 and 93 weeks of age. The
protocol allowed for the independent measurement of the strength of the forelimbs alone, as
well as fore- and hindlimbs taken simultaneously [31]. Mice were held by the base of the tail
and gently swung to allow the mice to grip the wire-mesh grid attached to a grip strength moni-
tor (Bioseb In Vivo Research Instruments). Once the mice gripped the grid, they were gently
pulled away from the apparatus. Maximum tension (g) before the mice released the grid was
recorded. For both grip strength recordings (forelimb only, and fore- and hind limbs together),
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mice were tested thrice. The average performance was taken for analysis. The apparatus was
thoroughly cleaned with 70% IMS between trials.
Swimming T-maze. Visuospatial cognition involving matching-to-sample tasks is known
to be impaired in patients with HD [39]. To probe cognitive deficits associated with cortical
dysfunction, animals were exposed to a visuospatial matching-to-sample and reversal task.
Due to the weight loss of animals at later time points, a food reward task was avoided to prevent
food restriction. Instead, an escape-learning paradigm was used in a swimming T-maze [31].
Cue learning, and the reversal of cue learning was assessed in a swimming T-maze at 13, 21,
34 and 49 weeks, using an adapted protocol [40]. The maze consisted of a horizontal arm (122
cm length, 12 cm width, 35 cm depth made from black, non-transparent plastic) bisected in
the center by a vertical arm (60 cm length, 12 cm width, 35 cm depth), filled with water made
opaque through the addition of a whitening agent (Marvel dried skimmed milk, Premier Foods,
UK). The maze was thoroughly cleaned every third day, and the water changed. A transparent
plastic square escape platform was submerged 0.5 cm, invisible under the water surface. Water
temperature was maintained at ~21˚C throughout the duration of the procedure.
For “cue learning”, the escape platform was pseudo-randomly located (location order picked
randomly out-of-a-hat), at either the left or right end of the vertical arm and was cued to the
presence of an illuminated desktop lamp directly over the escape platform. Mice were individu-
ally placed in the starting position (at the base of the vertical arm, opposite where it bisects the
vertical arm) and allowed to swim to the junction of the two arms. At this juncture, they made a
decision to swim either toward the light (i.e. escape), or away from the light (i.e. no escape before
being rescued after 10 sec). Mice were dried between trials. Mice were exposed to 12 trails per
day until they reached criterion (10 correct choices out of 12 successive trials, 83.3% correct
rate), whereby they began the second part of the trial, termed “cue reversal” learning. For cue
reversal training, the desktop lamp cue was now situated at the opposite arm to the escape plat-
form. Thus, mice were forced to re-learn the escape conditions. Cue reversal training was run
until the mice reached criterion (again, 83.3% correct rate), at which point the assessment was
complete.
Fear conditioning. Cued and contextual fear conditioning was used to probe cognitive
function in these mice at 11 weeks of age, using an adapted protocol [31, 41]. Experiments
were conducted using a standard fear conditioning system (TSE-Systems, Germany). The test
was divided into three days, day 1 “training”, day 2 “cue recall and extinction” and day 3 “con-
text recall”.
Day 1 “training”: The operant chamber was scented using a solution of 79.5% water, 19.5%
ethanol, 1% vanilla extract. Mice were individually placed in the arenas and exposed to the
conditioning protocol; three pairings of a conditioned stimulus (30 sec auditory tone), and an
unconditioned stimulus foot-shock (0.5 mA, 1 sec duration).
Day 2 “cue recall and extinction”: The operant chamber was thoroughly cleaned with 50%
ethanol to remove all vanilla extract odor. Monochrome patterned wall inserts and a plain
white floor insert were added to change the context of the operant chamber. Mice were indi-
vidually placed in the chamber and subjected to 25 exposures of the conditioned stimulus
(auditory tone), but no foot shock, in order to measure cued recall and extinction of condi-
tioned fear.
Day 3 “context recall”: The operant chamber was returned to the identical context as for
Day 1 with mice being placed in the operant chamber for 5 min with no conditioned or uncon-
ditioned stimuli to determine contextual recall of conditioned fear.
Throughout the duration of these tests, behavior was videotaped by a camera positioned
above the apparatus. Mouse immobility (a complete absence of movement except breathing)
was considered a measure of fear, scored by an investigator blinded to the experimental
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groupings. An inter-rater reliability of>95% confidence was achieved [31]. For cued recall
and extinction on Day 2, immobility over five summed conditioned stimulus (CS) exposures
(giving a total of 5, 30 sec blocks) was used for analysis. For contextual recall on Day 3, immo-
bility was expressed over the entire 5 min trial.
Odor discrimination. This test was conducted to probe olfactory function of mice at 10,
17, 39, 54, 80 and 94 weeks. Mice were habituated to plain white arenas (50 x 50 x 50 cm), for
10 min/day for two days prior to starting the test [31]. On the test day, two samples of mouse
litter were available for investigation over a total of 5 min. One sample being clean litter, the
other being soiled litter from unfamiliar sex-matched mice. Samples of litter were held in up-
turned Eppendorf tubes with 0.5 cm of the tips removed to allow the animal to smell the con-
tents. Behavior was videotaped from above and subsequently analyzed. Time spend investigat-
ing the tubes (nose pokes directly at the aperture of the tubes) was quantified by an investigator
blinded to both the samples and experimental groupings. Preference for the soiled litter was
expressed as percentage of time investigating soiled sample out of total time investigating either
sample. An inter-rater reliability of>95% was achieved. Arenas were thoroughly cleaned with
70% IMS between trials.
Social interaction. Social behaviors, as well as the ability to discriminate novelty, was
tested at 10 weeks of age using an adapted protocol [31, 42]. Test mice were habituated to plain
white arenas (50 x 50 x 50 cm) for 1 h. Two corrals (up-turned pen holders, Staples, UK) were
then positioned inside the arenas in reproducible positions, and the test mice were allowed to
habituate to the corrals for a further 30 min. During “exposure 1”, a sex-matched, 8 weeks old
C57Bl/6 mouse was positioned in one corral and the test mouse was allowed to investigate, but
not physically interact with the mouse for 5 min. This now “familiar” mouse was removed, and
following an inter-trial-interim of 30 min “exposure 2” was conducted, whereby the “familiar”
mouse was replaced back into the same corral and a different, “novel” C57Bl/6 mouse was placed
in the other corral. The test mouse was free to investigate either the familiar or novel mouse.
Behavior was videotaped from above and subsequently analyzed. Time spent investigating the
familiar and/or novel mice was measured by an investigator blinded to the experimental groups.
An inter-rater reliability of>95% was achieved [31]. Arenas and corrals were thoroughly cleaned
with 70% IMS between trials.
Magnetic resonance imaging
In vivo longitudinal MRI. WT and HdhQ150 mice were scanned in vivo, serially, a total
of seven times at 8, 15, 23, 36, 52, 81 and 94 weeks of age. Mice were anaesthetized using 5%
isoflurane along with a combination of medical air (0.7 L/min) and oxygen (0.3 L/min). Once
fully anesthetized, mice were positioned and fixed into a plastic frame, where anesthetic was
administered through a facemask. Mice were maintained under anesthesia, typically between
1–2% isoflurane for the duration of the scanning. Temperature was maintained through a
homeostatic heating airflow system and breathing rate monitored through a respiration bal-
loon positioned under the thorax (Small Animal Instruments, New York, USA). Post-scan-
ning, but prior to recovery, mice were administered 0.1 mL saline i.p. to abate dehydration.
Images were acquired on a 7 T horizontal bore MRI system (Varian, Paolo Alto, California,
USA), with a 100 Gauss gradient set insert and a 39 mm bore (transmission and receiver)
radiofrequency coil (Rapid, Germany). The scanner was controlled through VnmrJ software
(Varian, Paolo Alto, California, USA). Correct positioning of the mouse within the RF coil was
confirmed through a series of scouting images. A Multi-Echo-Multi-Slice (MEMS) scan was
then acquired (TR = 2500 msec, TE = 10 msec, echo train = 8, averages = 4, matrix = 128 x 128,
FOV = 20 x 20 mm, 156 μm in plane resolution, 30 coronal slices at 0.5 mm thickness, 21 min
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acquisition time). The typical signal-to-noise ratio (SNR) = 5.4, the typical white:grey matter
ratio (WGR) = 1.25. Coronal slices were positioned based on a reproducible anatomical
marker (the most visibly posterior part of the cerebellum).
Post-acquisition, all eight echoes were summed into a single structural image set. As previ-
ously described [30, 31], these images were used to manually delineate neuroanatomical struc-
tures in JIM Ver. 5.0 (Xinapse Systems, Alwincle, UK). Regions-of-interest (ROIs) consisted of
whole brain, cortex, striatum, hippocampus, and corpus callosum. ROIs were delineated by
two investigators blinded to the experimental groupings, and intra- and inter-rater reliability
was consistently 95% confidence. Details of neuroanatomical inclusion criteria and delinea-
tion guidelines were identical to those described previously [30]. All information outside of
the ROIs was subsequently masked out, the ROIs were then individually saved in NIFTI for-
mat. Volumetric data were calculated and processed semi-automatically using Python Ver.2.6
(Python Software Foundation). To measure changes in T2 relaxivity (reflective of tissue com-
position), maps of T2 signal intensity were obtained through a mono-exponential fit of the
eight echoes. The ROIs were superimposed onto the maps of T2 signal intensity allowing for
the generation of mean T2 relaxation times within each ROI. A small circular ROI was taken
for cheek muscle tissue T2 relaxivity in order to act as an internal control measure.
Ex vivo MRI. Following the final in vivo MRI scan, at 94 weeks of age, mice were anaes-
thetized using a terminal anesthesia Euthatal (Marial, Harlow, UK), and then transcardially
perfused with heparinized saline (50 units/ml), followed by Parafix (4% paraformaldehyde,
Pioneer Research Chemical Ltd., Essex, UK). Whole heads were removed and submerged in
Parafix and kept at 4˚C until ex vivo imaging. Post-mortem ex vivo MRI scans were taken.
These images were higher resolution compared to the in vivo scans, and did not suffer the
potential artifacts which can arise from live scanning (e.g. physiological movement), therefore
allowing a more precise measurement of more subtle changes in brain structures. The scanning
set-up was identical to that used for in vivo imaging. Correct positioning of the mouse head
within the RF coil was confirmed through a series of scouting images. An MEMS sequence was
then acquired (TR = 3000 msec, TE = 10 msec, echo train = 8, averages = 22, matrix = 192 x
192, FOV = 19.2 x 19.2 mm, 100 μm in plane resolution, 35 coronal slices at 0.5 mm thickness,
acquisition time for scan was ~3.5 hours). Typical SNR = 11.96, typical WGR = 1.54.
Tensor based morphometry. An un-biased whole-brain comparison of WT and
HdhQ150 mice at each imaging time-point was performed using an automated image process-
ing pipeline [43]. All scans were first registered with 6 degrees of freedom (dof) (to remove dif-
ferences in position and orientation using a rigid-body assumption) and 9 degrees of freedom
(to optionally remove global differences in scale using a growth model based on uniform scal-
ing), using a population-based approach which has proven robust in rodent imaging applica-
tions [33]. Then each scan was non-rigidly registered to the WT mean at the same time-point
using a high-dimensional fluid registration technique [44–46]. This technique models the
coordinate mapping between scans as the flow of a viscous fluid and can successfully map
large structural displacements, as well as smaller localized changes in shape. This technique
has previously been applied in other rodent models, e.g. structural remodeling in stroke [43].
The fluid registration results in a dense displacement field, which maps each point in the origi-
nal scan to the corresponding point on the reference mean. From this map, an estimate of
apparent volume difference (the Jacobian determinant) between the scan and the WT mean at
each voxel can be obtained. TBM analysis then applies voxel-wise non-parametric t-tests to
these volume difference estimates to determine the location of statistically significant differ-
ences in brain tissue volume of HdhQ150 compared with WT. Significance levels are corrected
for multiple comparisons across voxels using the False Discovery Rate (FDR). The analysis fol-
lowing 6 dof registration finds absolute volume differences (i.e. the fluid registration includes
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differences in brain size and the analysis finds absolute volume difference between regions).
Following 9 dof registration, volume differences are relative to whole brain volume, V (i.e. the
fluid registration does not include differences in global brain volume and the analysis finds
volume differences relative to whole brain volume). Collectively, these analyses allow for the
comparison of WT versus HdhQ150 at each time point (seven image sets in vivo and one ex
vivo), as well as the age-related change within each genotype (comparing all other time points
to the scan at 36 weeks of age when WT brains stopped growing). The image analysis approach
is described in more detail in [43].
Histology
Upon completion of ex vivo imaging, mice were perfusion-fixed with heparinized saline, fol-
lowed by 4% paraformaldehyde (PFA). Brains were removed from the skulls, rinsed in phos-
phate buffered saline (PBS) and stored in 30% sucrose in PBS (+0.05% sodium azide) until
sectioning. Coronal sections were taken serially at 50 μm thickness on a freezing microtome
(HM430 Microm, Thermo Scientific) and stored at -20˚C in tissue cryoprotective solution
(30% Ethylene Glycol, 25% Glycerol and 0.5% Sodium Azide in PBS) until staining. Histologi-
cal processing and data collection was performed identically to that described previously in
[30].
Immunohistochemistry. Sections were washed in PBS prior to incubation for 30 min in
3% H2O2 in PBS to quench endogenous peroxidase activity. Non-specific binding was blocked
with a 1 h incubation in 10% normal serum with 0.3% Triton X-100 in PBS. Sections were
then incubated overnight at 4˚C in primary antibodies against NeuN (1:500, Millipore, Wat-
ford, UK) or S830 (1:2000), raised against exon 1 HTT with 53 glutamines [47], prior to incu-
bation in appropriate biotinylated secondary antibody (Vector, Peterborough, UK) for 2 h at
RT, followed by 1 h incubation in an avidin-biotinylated-peroxide complex (1:100, Vector,
Northampton, UK). 3, 3’-diaminobenzidine (Sigma-Aldrich, Poole, UK) was used as the
chromagen.
Cortical thickness. Assessment of regional cortical atrophy was determined by thickness
measurements of primary motor cortex (M1) and primary sensory cortex (S1) on NeuN-
stained sections [30, 31]. In each region, 10 vertical lines were drawn covering all layers from
the most dorsal horn of the corpus callosum to the pial surface. From these measurements, the
mean length was calculated from 3 consecutive sections (approximately Bregma +1.10 mm).
Stereology of NeuN-stained sections. Unbiased stereological estimates of volume and
neuronal number were obtained using StereoInvestigator software (Microbrightfield, Willston,
VT). All stereological measurements were performed with the observer being blinded to the
experimental grouping. The Cavalieri method was used to obtain unbiased estimates of striatal
and M1 cortical reference volumes [48]. ROIs were defined by x1.6 magnification lens through
reference to neuroanatomical landmarks. For both the striatum and M1 cortex, equally spaced
sections (50 μm thickness each, 450 μm gap) were analyzed. As defined by Sadikot and Sasse-
ville [49], sections contained within the striatum were sampled anteriorly from the first
appearance of the genu of the corpus callosum (Bregma = +1.1 mm) to posteriorly at the first
evidence of a hippocampal formation (Bregma = -0.94 mm). The dorsal and lateral boundaries
consisted of the corpus callosum with the medial boundary being the lateral ventricles/internal
capsule. For sections rostral to where the dorsal 3rd ventricle has joined the lateral ventricles,
ventral boundaries become lateral ventricles/globus pallidus. The striatal volume was sampled
by 4–5 sections for both WT and HdhQ150. M1 cortex was measured anteriorly from +1.1
mm bregma to posteriorly -0.94 mm bregma from layers II to VI, as defined in a stereotaxic
atlas [50]. The absence of cortical layer IV (indicative of the S1 cortex) defined the lateral
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boundaries of M1, whereas medial boundaries consisted of the most dorsal part of the corpus
callosum. M1 was sampled by 4–5 sections for both WT and HdhQ150.
To obtain unbiased estimates of neuronal numbers, the optical fractionator was employed
as a stereological probe (coefficient of error<0.1). Section thickness and neuronal counts were
performed under oil immersion with the x100 objective (Zeiss) with a numerical aperture of
1.4. A sampling grid was applied appropriate to the structure measured (cortex = 200 μm x
200 μm, striatum = 400 μm x 400 μm) with a counting frame of 65 μm x 35 μm with a mean
thickness of 18 μm. Guard zones of 0.5 μm were applied at the top and the bottom of each
frame with a mean dissector height of 17 μm.
Quantitative analysis of S830. Evaluation of mHTT immunoreactivity in different brain
regions was performed using an intensity-based measurement of S830 staining [30, 31]. Non-
overlapping images (using fixed exposure and light intensities at x40) were obtained from 3
consecutive sections expressing the striatum or hippocampus, and 6 sections for the cortex. In
total, 30 striatal (10 per section), 60 cortical (10 per section) and 36 hippocampal subregion
(12 per section) images were taken. All images were captured in RGB using a live video camera
(JVC, 3CCD, KY-F55B), mounted onto a Zeiss Axioplan microscope.
Staining intensity was quantified using threshold-based analysis software (Image Pro Plus,
Media Cybernetics, IL, USA) assessing optical density of the immunoreactive product. Thresh-
old levels were chosen based on the minimum level of transmitted light needed to detect the
immunoreactive product on a scale of 0 (100% transmitted light) and 255 (0% transmitted
light) for each pixel. Two levels were taken to measure dense, nuclear mHTT inclusions (90),
and total aggregated mHTT staining (nuclear and extra-nuclear, 130); mean percentage
immunoreactivity area per field of view (FOV) was recorded.
Statistical analyses
Data was graphed using Prism Ver.5.0b (GraphPad Software, California, USA). Statistical analy-
ses were calculated using SPSS Statistics Ver.20 (IBM, Portsmouth, UK). All data were screened
for statistical outliers using Grubbs’ Test (GraphPad Software, California, USA). Grubbs’ test
calculates a z ratio for each value within a given dataset (determined through subtracting each
value from the group mean, and dividing it by the standard deviation). If the z ratio for any
given value is greater than those proposed by Grubbs for that population size, it is considered
an outlier. If this was the case, the value was excluded from analysis. Due to either animal loss,
or occasional missing data samples and removal of statistical outliers (total absent data samples
for male WT = 8, male HdhQ150 = 9, female WT = 10, female HdhQ150 = 9), the number of
animals varied for each test at different time points. A table summarizing the number of subjects
included for each measure and the reason for exclusion can be found in S1 Table.
The acquired datasets can be separated into those that were collected longitudinally, those
acquired at a single time point, correlational analyses, as well as tensor based morphometry
statistics.
Longitudinal datasets. These datasets refer to tests where data was collected at more than
one time point and include: body weight assessment, rotarod, locomotor activity, grip strength
measurements, swimming T-maze, odor discrimination, and social interaction, as well as mea-
surements of volumetry and T2 relaxivity through MRI. It was not possible to compute a
repeated measures ANOVA due to missing values at different measurement times. To probe
the influence and interaction of genotype and gender across time, a three-way ANOVA was
applied (Genotype, Gender and Age, as between-subject factors).
Repeated measures dataset. To determine whether mice exhibited cued fear conditioning
and extinction (i.e. a form of re-learning that the CS is no longer aversive with repeated
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exposure), a repeated measures ANOVA was used (repeated Tone (CS) exposure as within-
subject factor, Genotype and Gender as between-subject factors). Post-hoc tests with a Bonfer-
roni correction for multiple comparisons were applied where appropriate. All main effects
from ANOVAs can be found in S2 Table.
Datasets taken at a single time-point. These data refer to tests that were only conducted
once during the study, such as histological measures taken through stereology. To probe the
influence of genotype and gender on these measures, a two-way ANOVA was applied (Geno-
type and Gender as between-subject factors). Post-hoc tests with a Bonferroni correction for
multiple comparisons were applied where appropriate. All main effects from ANOVAs can be
found in S2 Table.
For the histological quantification of mHTT, there was an absence of immunoreactivity in
the WT mice. This marker, within this group, was therefore not included in the analysis. To
compare levels of mHTT across various brain regions, and probe the influence of gender on
this measure a two-way ANOVA was applied (Region and Gender as between-subject factors).
A post-hoc test was conducted for multiple comparisons, with a Bonferroni correction, com-
paring male and female HdhQ150 mice at each brain region.
Correlative analyses. The Pearson Correlation Coefficient was used for all correlative
analyses. To account for multiple correlations of the same data, the significance level was cor-
rected using a Bonferroni correction by dividing the standard p value (0.05) by the number of
comparisons made, resulting in an appropriate adjusted p value for each dataset.
Tensor based morphometry statistics. As described in [43], a non-parametric two-tailed
t-statistic, assuming unequal variance between groups, is computed at each voxel (approxi-
mately 42,000) in the brain. Permutation-testing is used to assess significance. The effective
number of permutations at each voxel is increased by pooling null-distribution statistics from
other voxels to allow for accurate multiple comparisons correction using the False Discovery
Rate (FDR) [51]. The minimum number of required permutations is approximately (number-
of-voxels / FDR-significance-level) = 42,000 / 0.05 = 840,000.
Results
Lack of weight gain in HdhQ150 mice
A decrease in animals’ weight is a general physiological indicator of poor health. There was
a steady weight gain in WT and HdhQ150 animals for males (Fig 1B) and females (Fig 1C). Male
HdhQ150 mice exhibited normal weight gain until week 35 [F(Genotype X Age)21;788 = 31.704,
p<0.001), and female HdhQ150 mice until 45 weeks of age [F(Genotype X Gender)1;788 = 15,
772, p<0.001] (S2 Table for all statistical results). Although there was no significant weight loss
in both HdhQ150 genders, there was no longer a weight gain, as observed in WT of both genders
[F(Genotype)1;784 = 1197.939, p<0.001]. Body temperature decreased with age [F(Age)20;754 =
113.1, p< .001], with no genotype effects for male or females [F(Genotype X Gender) 1;754 =
0.022, n.s.]. However, females’ body temperature was overall higher than males by ~1˚C [F(Gen-
der) 1;754 = 240.471, p<0.001].
A slowly progressive motor function decline
One of the hallmarks of the clinical horizon of Huntington’s disease is the onset of motor dys-
function. The rotarod is a commonly used task to assess motor coordination. Interestingly,
here at 39 weeks of age, HdhQ150 animals of both males (Fig 2A) and females (Fig 2B) per-
formed better on this task than WT [F(Genotype) 1;106 = 8.211, p<0.01], with a gradual decline
of performance by 55 weeks of age [F(Genotype X Age) 2;106 = 9.793, p<0.001]. At the late
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stage WT and HdhQ150 did not exhibit a significant difference in performance, although their
latency to fall from the rod further decreased [F(Age) 1;106 = 74.303, p<0.001].
General ambulant locomotor activity (open field) diverged with the rotarod performance.
Notably, for male subjects there was no significant difference in performance up to 38 weeks
of age, whereas for females, there was already evidence of a decreased performance that accen-
tuated with time [F(Genotype X Gender) 1;213 = 3.918, p<0.05] at the start of testing (16 weeks
of age). At the final time point (93 weeks of age), male HdhQ150 revealed a 34% decreased in
locomotor activity (Fig 2C), whereas female HdhQ150 animals’ performance showed a 39%
attenuation compared to controls (Fig 2D). Genotype was a major factor in locomotor activity
[F(Genotype) 1;213 = 40.264, p<0.001], as was age [F(Age) 1;213 = 14.481, p<0.001].
For grip strength, which measures fine motor behavior and muscle strength, male
HdhQ150 mice already revealed a significant difference to WT strength at 16 weeks of age (the
earliest time point tested). This deficit persisted, but only started to decline after 26 weeks of
age (Fig 2E). Although female HdhQ150 developed also a deficit in grip strength (Fig 2F), the
emergence of this was delayed and only became apparent after 38 weeks of age with a gradual,
but steady decline. The deficit in male HdhQ150 was 7% greater at the final time point com-
pared to females. The combined fore and hind limb strength were comparable to WT up until
38 weeks of age, when a gradual decrease was observed for both male (Fig 2G) and female
HdhQ150 mice (Fig 2H). However, it is important to note that this decrease brought HdhQ150
animals back to the level of strength they exhibited at 16 weeks, indicating that the magnitude
of decrease is different in nature compared to that observed for locomotor activity, where per-
formance was 55% less than at 16 weeks of age.
Lack of a robust cognitive impairment
Cognitive deficits are also associated with the clinical symptomatology of HD, but little is
known about the presence, as well as the evolution, of cognitive performance in mouse models
of the disease. A matching-to-sample task was implemented in the swimming T-maze to probe
visuospatial cognition. At 13 weeks of age, male HdhQ150 mice took significantly longer to
learn the task (Fig 3A), whereas females did not exhibit a deficit (Fig 3B). Male HdhQ150 mice
consistently performed worse, but this difference was not significant. Females in contrast did
not show a deficit in this task until 34 weeks, but performed significantly worse than WT at 49
weeks of age. Cue reversal did not initially show any impairment, but by 34 weeks of age male
HdhQ150 mice performed poorer compared to WT (Fig 3C), although the high variability in
HdhQ150 did not reveal a statistically significant result. Female HdhQ150 actually showed a
significantly better performance at 34 weeks of age, although performance was again compara-
ble to WT at 49 weeks (Fig 3D). Males therefore demonstrated a mild deficit on this task,
whereas females performed well. Acquisition of the swimming water maze was halted at 49
weeks of age as we previously observed a significant number of unexpected deaths following
swimming maze performance in aged animals.
Additional cognitive tasks also failed to reveal a major deficit. Fear condition in male
HdhQ150 mice showed a slightly poorer performance compared to WT (Fig 3E), but the per-
formance of female HdhQ150 animals was equivalent to WT (Fig 3F). Odor discrimination,
which is often considered an early biomarker in neurodegenerative disease [52, 53], revealed
an early difference between WT and HdhQ150 at 10 weeks of age [F(Genotype X Age) 5;212 =
3.028, p<0.05], but did not show any further performance differences in male (Fig 3G) or
female HdhQ150 mice (Fig 3H). Probing of social interaction failed to reveal any significant
effects for male (Fig 3I) or female HdhQ150 mice (Fig 3J), but there was an indication of a
poorer performance for male mice beyond 39 weeks of age. Overall, there was a lack of robust
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Fig 2. Performance at motor-related tasks. Both male (A) and female (B) HdhQ150 mice performed better on the rotarod
compared to controls, but performance of all animals deteriorate with no difference between HdhQ150 and controls beyond 55
weeks of age. HdhQ150 male (C) and females (D) developed a general age-related hypoactivity in an open-field arena. Fore-
limb grip strength capactiy was lower in HdhQ150 male mice from as early as 16 weeks of age (E), whereas a deficit in female
HdhQ150 was detectable from 53 weeks (F). Similarly, fore- and hind-limb grip strength, taken together, was progressively
lower in both male and female HdhQ150s versus WTs (G & H). All data presented as means ± SEM; *p < .05, **p < .01,
***p < .001.
doi:10.1371/journal.pone.0168556.g002
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evidence to indicate that HdhQ150 mice exhibit impairments in these cognitive domains (i.e.
visuospatial processing, memory, odor discrimination, social interaction).
Performance on motor and cognitive tasks was mostly uncorrelated
The battery of behavioral assessments was designed to evaluate different domains and in nor-
mal animals should be orthogonal (i.e. independent of each other). This indeed was the case
for the early time points (9–13 weeks of age; S3 Table). Between 16–54 weeks, the only correla-
tion that survived Bonferroni correction was for animals where grip strength in the forepaws
correlated with grip strength of all four limbs (r>0.7, p<0.001). During the final stages, this
was also evident in male animals. Locomotor activity was also correlated (r>0.6, p<0.001)
with grip strength in the final stages of the disease.
Brain growth arrest in HdhQ150 mice is followed by a slowly progressive
regional atrophy
To provide a concomitant evaluation of brain anatomy, T2-weighted MR images were acquired
that afforded a detailed assessment of changes in brain structure and tissue signal (Fig 4). A
region-of interest (ROI) approach was used to measure volumes of anatomical structures (Fig
5). At 8 weeks of age, WT and HdhQ150 animals showed equivalent whole brain volumes, but
these revealed a slower growth up to 15 weeks of age and eventually growth arrest until 23
weeks of age (Fig 5A & 5B). After 23 weeks of age a very slow but progressive brain atrophy was
observed. This global atrophy is driven by regional changes. Striatal volumes revealed significant
differences at 15 weeks, with males exhibiting no growth until 23 weeks before progressive atro-
phy led to a 26% decrease in volume by 94 weeks (Fig 5C). This was the steepest decrease in
Fig 3. Performance at non-motor-related tasks. Cued learning (A & B) and cue reversal learning (C & D),
assessed in a swimming T-maze, was generally intact in HdhQ150 mice versus WTs with the exception of an
apparent deficit in cued learning in male HdhQ150 mice at 13 weeks only (A). Cue recall and extinction was
similar between WT and HdhQ150 mice irrespective of gender at 11 weeks of age (E & F). Both male and
female HdhQ150 had a lower preference for soiled little, versus WTs, at the odor discrimination task at 10
weeks only (G & H). There was no difference in social interaction behaiovurs at any age investigated (I & J). All
data presented as means ± SEM; *p < .05.
doi:10.1371/journal.pone.0168556.g003
Fig 4. Longitudinal in vivo MR images. Summed T2-weighted structural group-images for WT and HdhQ150 mice from 8 to 94 weeks of age.
doi:10.1371/journal.pone.0168556.g004
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regional volume. In females, striatal volume showed slower growth up to 15 weeks of age with
no growth in volume up to 23 weeks of age (Fig 5D). Cortical volume for male (Fig 5E) and
female HdhQ150 (Fig 5F) revealed slower growth up to 23 weeks of age before a growth arrest
period set-in that lasted until 52 weeks of age. Cortical atrophy was seen thereafter with 12%
volume decrease leading to a 23% difference in volume with WT. The hippocampus (Fig 5G &
5H) saw a similar pattern of slower growth (8–23 weeks) followed by a period of stable volume
(23–52 weeks) that eventual lead to shrinkage of tissue (21%). Interestingly, corpus callosum
also saw a brief period of slower growth, but saw an early decrease in volume from 15 weeks
onwards, potentially indicating important differences in connectivity that are not necessarily
reflected in tissue volume changes (Fig 5I & 5J). Although there was little correlation between
regional volumes in male and female WT mice, HdhQ150 animals revealed a high degree of
commonality in structural changes between regions (S4 Table). Striatal, cortical and hippocam-
pal volume were all highly correlated with whole brain volume (r>0.6, p<0.001). Striatal vol-
umes in HdhQ150 were also correlated with hippocampal and cortical volumes, as well as that
of the corpus callosum (r>0.4, p<0.001). However, corpus callosum was not correlated with
cortical or hippocampal changes in HdhQ150 animals.
Compaction of tissue is reflected in a T2 signal change (S5 Table). Over time there was a signif-
icant decrease in T2 signal in the striatum [F(Age) 1;246 = 5.522, p<0.001], cortex [F(Age) 1;246 =
8.194, p = 0.001], hippocampus [F(Age) 1;246 = 4.785, p<0.001], corpus callosum [F(Age) 1;246 =
30.229, p<0.001] and muscle [F(Age) 1;246 = 19.762, p<0.001]. The T2 signal decreased in the stri-
atum [F(Genotype X Age) 1;246 = 2.572, p = 0.066] and hippocampus [F(Genotype X Age) 1;246 =
2.345, p<0.05] as the animals grew older. The only overall genotype effect was in muscle [F(Geno-
type) 1;246 = 4.714, p<0.05]. A gender effect was also evident in striatum [F(Gender) 1;246 = 5.872,
p<0.05], cortex [F(Gender) 1;246 = 3.105, p = 0.079] and hippocampus [F(Gender) 1;246 = 5.295,
p<0.05]. Apart of a correlation between cortical and hippocampal T2 values (r>0.58, p<0.001),
there were no associations between changes in T2 in any of the examined regions. These signal
changes thus indicate the effect of aging on tissue, but also that the signal for HdhQ150 animals
evolves differently in these brain regions over time.
Tensor-based morphometry dissociates global and regional atrophy
To probe subtle sub-regional changes using an unbiased method that does not rely on prede-
fined ROIs, tensor-based morphometry (TBM) visualized voxels that underwent statistically
significant changes indicative of volumetric effects (Fig 6). A 6DOF registration provides a
direct comparison between WT and HdhQ150 indicating a gradual decrease in volume start-
ing at 15 weeks. Subcortical areas were first affected, although the motor cortex revealed some
atrophy early-on. To provide a direct regional comparison, that removes overall size effects, a
9DOF comparison was performed. This revealed that these early changes at 15 and 23 weeks
of age were mostly driven by an overall size effect, as no direct regional effects were evident. In
males, at 36 weeks regional effects were very localized to the motor and somatosensory corti-
ces, but also subcortical structures, such as the striatum and thalamus. In this direct compari-
son, females only exhibited statistically significant changes at 81 weeks of age. These were akin
to male subjects at this age, but with more widespread changes evident. In particular, there was
an expansion of cortical atrophy and enlargement of ventricles. These results demonstrate that
overall brain atrophy is a major driver in the disease process, although certain regions are
more affected than others; these regional effects appear to be a secondary and potentially less
important pathological event.
Due to the significant change in brain growth observed over the assessment period, a com-
parison across time that uses the first time point (8 weeks of age) as a baseline would be
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inappropriate. HdhQ150 brains reached their largest size at 36 weeks, affording a visualizing of
growth, as well as atrophy, in relation to this time point (Fig 7). As indicated by the ROI analy-
sis, there was a slower brain growth between 8 and 36 weeks of age for HdhQ150 animals of
both genders (as indicated by the smaller decrease in volume at 8 weeks of age). Conversely,
after 36 weeks of age a greater decrease in the cortex and striatum was observed in HdhQ150
mice compared to WT, in contrast to a greater enlargement of the ventricles. Sub-cortical
areas, such as the thalamus, appeared largely unaffected by the condition, although some
decrease was observed at the final time point, potentially reflecting a general atrophy.
Ex vivo MRI scans provided a higher spatial resolution with improved signal-to-noise ratio
in the absence of physiological motion allowing a more detailed sub-regional comparison of
WT with HdhQ150 mice (Fig 8). However, 9DOF are required for these subtle regional
Fig 5. Quantification of regional brain atrophy. A gradual atrophy of whole brain atrophy was evident in
male (A) and female (B) HdhQ150 compared to controls. HdhQ150 brain regions demonstrated progressive,
age-related reduction in volume compared to WTs, irrespective of gender. Striatal volume loss in male
HdhQ150 (C) was greater than for females (D). This difference between male (E) and females (F) was also
evident for the cortex. Although hippocampal volume differences were delayed compared to striatum and
cortex, both male (G) and females (H) showed growth arrest and atrophy. Volumetric differences were also
apparent in the corpus callosum with males (I) showing non-significantly lower volumes compared to females
(J) with evidence of atrophy in both genders beyond 15 weeks of age. All data presented as means ± SEM;
*p < .05, **p < .01, ***p < .001.
doi:10.1371/journal.pone.0168556.g005
Fig 6. TBM Group comparison at each time point. Maps of local volumetric changes in male and female
WT compared to HdhQ150 mice revealed significant sub-regional changes. Images are presented either as
global volume changes (6 degrees of freedom, DOF) or region-specific changes which account for whole
brain differences (9DOF). Color scales represent statstically significant volume hypertrophy (warm colors) or
atrophy (cold colors) with only voxels surviving correction for multiple comparisons (False Discovery Rate with
q<0.05) being shown. Early atrophy in the striatum and motor cortex is evident before other regions are
gradually affected. It is also evident here that 6DOF reveals more dramatic changes which potentially
indicates overall brain growth related effect as compared to region-specific effects as revealed in the 9DOF.
doi:10.1371/journal.pone.0168556.g006
Characterization of the HdhQ150 Mouse Model of HD
PLOS ONE | DOI:10.1371/journal.pone.0168556 January 18, 2017 17 / 33
nuances to be apparent, with 6DOF only revealing a blanket decrease in almost all structures.
Using 9DOF, sub-regional changes, notably within the cortex, become apparent with the outer
layers undergoing greater loss. The motor and somatosensory regions showed a greater extent
of atrophy than the enthorhinal cortex. In contrast, the striatum was uniformly decreased. The
septal areas also appeared to be affected, but it is possible that these were spill-over effects due
to the decreased volume in the striatum. A very subtle decrease in the thalamic area was also
becoming apparent. The ventricles and adjacent areas (such as the hippocampus) revealed
increases. These changes were fairly consistent across both genders although minor differences
were evident especially in regions with subtle changes.
Only late stage brain atrophy correlates with behavioral impairments
To investigate how these structural changes relate to the behavioral performance of WT and
HdhQ150 mice, correlations were performed between behavioral and MRI measures (S6
Table). After correcting for multiple comparisons, only a few random correlations emerged up
to 49–54 weeks of age. At this stage, a pattern emerged with grip strength of all paws being
Fig 7. Age-related evolution of sub-regional changes in HdhQ150 brains. To compare sub-regional changes over time, all
MRI scans were co-registered to the 36 week time point as this represented the time point with the largest volume (9DOF) and the
clinical horizon. This afforded a statistical comparison of tissue changes (decreases in cold colors, increases in warm colors) in
either time direction for either WT or HdhQ150 with a correction for multiple comparison (FDR with q<0.05). These results indicate
a slower growth (cold colors) of striatum in HdhQ150 animals with a greater decrease (cold colors) in striatum and cortical regions
beyond the clinical horizon.
doi:10.1371/journal.pone.0168556.g007
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correlated significantly with atrophy of the whole brain, striatum, cortex and hippocampus
(all r>0.7, p<0.001), but not corpus callosum. No correlation with T2 signal intensity was evi-
dent at this time point. After 79 weeks of age this correlation also extended to the forepaw only
grip strength (all r>0.7, p<0.001), but not for hippocampus (r = 0.68, n.s.). Locomotor activity
showed the same correlations with whole and regional brain volumes, including hippocampus
(all r>0.7, p<0.001), except corpus callosum (r = 0.677, n.s.). T2 signal intensity measures essen-
tially revealed the same pattern of correlations as volume changes with behavioral performance
Fig 8. TBM on high resolution ex vivo T2-weighted MR images. To reduce potential partial volume effects in sub-regional
comparisions ex vivo high resolution MR images were acquired to achieve a spatial resolution 2.5 higher than in vivo, as well as
a >2x higher SNR, while avoiding motion related artefacts. This afforded a more precise investigation of subtle effects that might
not be evident on in vivo images. A more defined sub-regional pattern of statstical differences between WT and HdhQ150 was
evidence using this approach. Color scales indicate statstically significant volume decreases (cold colors) and increases (warm
colors) with correction for multiple comparisons (FDR with q<0.05).
doi:10.1371/journal.pone.0168556.g008
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at these later stages of the disease. These later-stage correlations were expected considering that
behavioral performance and MRI measures by themselves are highly correlated, indicating a
common path for all measures [30, 31].
Neurodegeneration and mHTT in striatum and cortex
To investigate the underlying molecular and cellular changes of this anatomical atrophy, histopath-
ological studies investigated the distribution of aggregated mHTT, as well as neuronal loss. The
presence of aggregated mHTT within different regions was revealed by immunohistochemistry
(Fig 9A). Given that mHTT is absent in WT mice, it was only quantified in HdhQ150 animals to
provide a region and gender comparison. The presence of nuclear mHTT inclusions was consis-
tent with regions that contained a high neuronal density, such as the hippocampal subfields (Fig
9B). The nuclear inclusion load was also higher in striatal cells than in the cortex. Although there
was no significant difference between males and females, females tended to have more nuclear
inclusions than males. These general regional differences were also evident for total aggregated
mHTT (Fig 9C) with no significant gender effect. However, compared to nuclear mHTT, total
aggregated mHTT showed lower levels in the dentate gyrus and CA3, whereas the nuclear content
was higher for females in these regions compared to male HdhQ150 mice. Interestingly total aggre-
gated mHTT load in the striatum was only highly correlated with CA1 (r = 0.919, p<0.001) and
CA2 (r = 0.837, p<0.001), whereas nuclear mHTT revealed correlations of cortex with striatum
(r = 0.777, p<0.001), dentate gyrus (r = 0.961, p<0.001) and CA3 (r = 0.846, p<0.001) (S7 Table).
To determine if neurodegeneration was a major determinant of atrophy in the striatum and
cortex, neuronal number and density were quantified using stereological methods (Fig 10A).
At 94 weeks of age, there was a 18% decrease in neurons in the striatum (Fig 10B) of male
HdhQ150 mice, but the genotype comparison did not reach the criterion for significance [F
(Genotype) 1;34 = 4.016, p = 0.054]. There was also no statistically significant decrease in the
M1 cortex for both genders [F(Genotype) 1;34 = 2.249, n.s], with a 14% decrease for male
HdhQ150 and 13% decrease for females (Fig 10C). Neuronal density was slightly increased
(9%) for HdhQ150 animals in the striatum (Fig 10D), but did not reach statistical significance
[F(Genotype) 1;34 = 2.572, n.s]. Likewise, in the cortex, a 11% increase was evident, but did not
reach significance (Fig 10E) [F(Genotype) 1;34 = 2.928, p = 0.097]. However, an increase in
neuronal density and loss did translate into atrophy of the cortex (Fig 10F) and this was evi-
denced by a significant decrease in M1 [F(Genotype) 11034 = 49.276, p<0.001] and S1 cortical
thickness [F(Genotype) 1;34 = 59.446, p<0.001]. None of these histological measures revealed a
gender effect. However, a correlational analysis revealed a gender effect with female WT and
HdhQ150 M1 neuronal counts (r = 0.699, p<0.001), density (r = 0.683, p<0.001) and volume
(r = 0.673, p<0.001) correlating with their striatal counterparts (S8 Table). Although in males
there were also correlations (r>0.5, n.s.), these did not reach statistical significance. In contrast
in males, statistical significant correlations were found between the number of striatal neurons
and volume (r = 0.745, p<0.001). In females this correlation (r = 0.526, n.s.) was not significant
after multiple comparison correction.
Histopathological measures are poor predictors of behavior or MRI
measures
To determine if there was an association between histopathological measures and behavioral
changes, a correlational analysis was performed. No significant correlations were evident
between mHTT levels and behavioral measures in HdhQ150 animals (S9 Table). When both
genders were combined for WT or HdhQ150 significant correlations (S10 Table) were evident
for grip strength forepaws (males r = 0.672, p<0.001), as well as all four paws with striatal
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volume (males r = 0.711, p<0.001; females r = 0.834, p<0.001). M1 cortical volume in males
also correlated with forepaw grip strength (r = 0.504, p<0.001). In females, a strong correlation
was also apparent (r = 0.585, ns), but this was not statistically significant after correction for
multiple comparisons. In summary, a robust and strong association between histopathological
measure and behavioral changes was not identified.
A general lack of correlations was also evident for mHTT and MRI measures (S11 Table),
with the only exception being a very strong significant negative correlation between nuclear
inclusion levels in the hippocampal CA3 region and T2 relaxivity in the cortex (r = -0.958,
p<0.001) of males. Cortical relaxivity also correlated with nuclear inclusions in all other
regions (r>0.5), but these did not reach statistical significance after correcting for multiple
comparisons. Females did not show these high levels of correlation. Total aggregated mHTT
in general exhibited weak correlations with MRI measures (r<0.3). T2 relaxivity also did
not reveal any correlation with neuronal measures (S12 Table). For the combined WT and
HdhQ150, significant correlations were present for striatal volume by histology and whole
brain (male r = 0.761, p<0.001; female r = 0.718, p<0.001) and hippocampal volume by MRI
(male r = 0.738, p<0.001; female r = 0.697, p<0.001). In females, histology-based striatal vol-
ume was also significantly correlated with MR-based striatal (r = 0.712, p<0.001) and cortical
volumes (r = 0.686, p<0.001). In males, these correlations did not survive the correction for
multiple comparisons. There were no correlations for neuronal density or neuronal numbers
with MRI measures. The lack of correlations between mHTT aggregation and neuron num-
bers with MRI measures further indicates that other factors contribute to macroscopic tissue
changes in Huntington’s disease.
Discussion
Establishing the neurobiological cascade of pathological changes and identifying pre-manifest
biomarkers is highly dependent on the use of animal models of HD. We here characterized
the HdhQ150 knock-in model of HD to reveal a delayed onset of motor signs accompanied by
regional volumetric brain changes. The behavioral manifestation occurred around 36 weeks
of age, with pre-manifest changes in striatum, cortex and hippocampus evident. At 94 weeks
(2 years of age), HdhQ150 exhibited widespread mHTT deposits. However, there was no
strong correlation between behavioral, MRI and neuropathological measures. Although these
measures all decreased with time and it is tempting to associate these changes with each other,
the lack of a correlation between these implicate additional factors. This characterization indi-
cates that the HdhQ150 model is useful to identify and further investigate pre-manifest bio-
markers, but that there is still an insufficient understanding of the neurobiological cascade to
link mHTT deposits with the emergence of a clinical horizon.
HdhQ150 mice exhibit a slowly progressive brain atrophy with motor
impairment
The key features of Huntington disease are a slowly progressive neurodegeneration accompa-
nied by motor impairments, as well as the emergence of cognitive deficits [3]. The HdhQ150
Fig 9. mHTT accumulation in HdhQ150 mice. (A) Sample S830-stained brain sections of a WT and HdhQ150
mouse. Threshold-intensity-based analysis was used to descriminate nuclear mHTT inclusions versus total
aggregated mHTT levels in the striatum (STR), cortex (CTX), dentate gyrus (DG), hippocampal CA3 subfield
(CA3), hippocampal CA2 subfield (CA2) and hippocampal CA1 subfield (CA1). There were no significant
differences in mHTT levels between male and female HdhQ150 mice in the regions investigated. All data
presented as means ± SEM.
doi:10.1371/journal.pone.0168556.g009
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knock-in model revealed motor deficits that are evident at 36 weeks of age (9 months) with a
slowly progressive phenotype. However, grip strength of forepaws indicated even earlier defi-
cits occurring in male HdhQ150 animals at 9 weeks of age, although a decline in strength only
becomes progressive after 38 weeks of age, which is consistent with a previous report of motor
dysfunction in this model [16]. However, this motor dysfunction was only evident in behav-
ioral tasks that did not rely on balance, with an increase in weight and size in WT animals pro-
ducing a poor performance on the rotarod test. Although we did not find any cognitive
dysfunction in the test battery used here, impairments in the water maze and prepulse inhibi-
tion have been reported as early as 3–4 months of age [16]. The “clinical horizon” of HdhQ150
animals therefore manifests itself at approximately 36 weeks (6 months) of age. Interestingly,
this is also the time point where the most significant shift in brain structures was evident.
Prior to 36 weeks of age, the growth of most brain regions was slower for the HdhQ150
mice, whereas beyond this point, a progressive atrophy of the structures became apparent.
Growth of the striatum was already stymied at 15 weeks of age. Although female HdhQ150 still
demonstrated some growth until 15 weeks of age, this was not the case for males, potentially
indicating a difference in pathology that can explain the more severe behavioral phenotype
observed in males. Nevertheless, other regions, such as cortex and hippocampus underwent a
prolonged slow growth up to 23 weeks, with no further growth between 23–36 weeks. This
period could be a tipping point, where slow growth and atrophy reach equilibrium. It is con-
ceivable that neurodegeneration occurs throughout development and this underlies the slow
growth observed here. The slow regional brain growth in WT mice beyond 36 weeks suggests
that the progressive decline observed in HdhQ150 is no longer compensated by growth. The
slow growth in the striatum and cortex observed in HdhQ150 might actually reflect neurode-
generation, which is masked by concurrent growth. In human studies, no extensive longitudi-
nal MRI studies from pre-manifest to late stage disease have been reported. A smaller basal
ganglia volume is generally considered atrophy due to a cross-sectional comparison [51, 54],
but serial measurements for 2 years in pre-manifest patients potentially suggest compensatory
anatomical changes preceding the manifestation of HD [55].
The TBM comparisons revealed that sub-regional changes were more evident with male
HdhQ150 animals, as evidenced by a smaller striatum, thalamus and motor cortex at 15 weeks
of age. These volume changes were exacerbated with time in terms of regional distribution, as
well as magnitude. As the structural changes in the striatum became more pronounced, atro-
phy in the cortex also became apparent. This spatiotemporal evolution progressed to a point
whereby the regional atrophy did not progress further. Indeed, whole brain volume showed a
decrease between 52 and 81 weeks, but then leveled off between 81–94 weeks. Females showed
the same pattern of spatiotemporal evolution, but its onset was delayed. Nevertheless, at 94 weeks
both male and female HdhQ150 displayed a very similar pattern and magnitude of change. In
females, the decline observed after growth arrest was greater than in males. Although estrogen
has been suggested to act a neuroprotective agent [56], the rapid decline of the striatum and cor-
tex in females indicates that the later onset in atrophy is more likely due to a stronger compensa-
tory growth in these animals, rather than a reduction in neurodegeneration. Although there is
evidence here of significant neuronal loss in striatum and cortex at 94 weeks, it is unclear if
Fig 10. Histological analyses of NeuN-stained sections. (A) Sample NeuN-stained brain sections of a WT
and HdhQ150 mouse. Although HdhQ150 mouse neuronal numbers were consistently lower than those of
their WT controls, there was no significant difference in neuronal counts in the striatum (B) or M1 cortex (C).
Similarly, despite consitently higher neuronal density levels in HdhQ150s, there was no significant difference
compared to WTs in striatum (B) or M1 cortex (E). There was substantial M1 and S1 cortical thinning in
HdhQ150 mice (F).
doi:10.1371/journal.pone.0168556.g010
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indeed neuronal loss is observed in the pre-manifest stage (i.e.<36 weeks) or if the volumetric
difference is due to tissue compaction, as observed in the R6/2 model at 14 weeks of age [30].
Indeed, nuclear inclusions are densely distributed at 5 months of age [17], with gene expression
changes being mostly related to chromatin organization at 6 months and intracellular signaling
at 18 months [26].
Contrasting N-terminal fragment with full-length knock-in models
R6/2 mice exhibit a rapidly progressing phenotype with a very significant motor dysfunction
and premature death [57]. There is also evidence that the striatum does not exhibit a normal
growth pattern, with no further increase in volume beyond 4 weeks of age. Cortex exhibits a
significant decrease in volume after 4 weeks of age. As the R6/2 at 14 weeks of age do not
exhibit actual neuronal loss [30], this further suggests that initial regional changes in the brain
are not reflective of neurodegeneration per se, but other tissue changes, such as increased neu-
ronal density and reduction in extracellular space. Indeed, R6/1 mice that live longer than R6/
2 exhibit neuronal loss at 19 weeks of age [30, 31]. Although these two mouse lines are more
aggressive in their behavioral phenotype, including premature death, they nevertheless indi-
cate that early brain tissue changes are not necessarily linked to a classical loss of neurons, but
other changes precede this phenomenon [18, 20]. In HdhQ150 animals, the prolonged pre-
manifest phase that is characterized by thwarted regional growth is likely to reflect similar
changes.
The robust and severe behavioral phenotype of motor and cognitive deficits in the R6/2
[30] and R6/1 model [31] contrasts with the milder signs observed in HdhQ150. The lack of
correlation with structural changes, even early pre-manifest changes apparent on anatomical
T2-weighted scans, suggest that cellular dysfunction precedes neuronal loss [18, 26], but that
other tissue changes that are reflected in gross morphological anatomical differences precede
these functional deficits. Expression of mHTT in specific cellular phenotypes, such as astrocytes
and neurons, can help to address this issue [58]. Insufficient clearing of excitotoxic glutamate by
compromised astrocytes [59, 60], as well as a different reactivity, could all be contributing fac-
tors. Moreover, there is a general lack of consideration of the extracellular space (20% of total
brain volume), which at least in R6/2 is reduced [30], given a decrease in tissue volume in the
absence of neuronal loss leading to an increase in neuronal density.
The consistent characterization of different HD models using the same methodology allows
us a direct comparison of how differences in introducing mutant HTT affects the emergence
and presentation of molecular pathology and the causal cascade that ensues [14]. The lower
transgene expression levels in R6/1 animals compared to R6/2 afforded a longer lifespan due
to a milder phenotype that was evident in a slower progression of the condition in terms of
behavioral deficits, as well as brain atrophy [30, 31]. Importantly, this slower phenotype in
R6/1 produced neuronal loss that was not evident in R6/2. Still, there remains a disconnect
between gross anatomical changes, as well as neuronal loss, and behavioral dysfunction [2].
This was also the case here in the HdhQ150, which had a similar repeat length to R6/2, but sur-
vived significantly longer with a phenotype developing much more slowly, reaching a clinical
horizon at 36 weeks rather than 4–6 weeks in R6/2 mice. The R6/2 and R6/1 mouse models are
therefore best suited to “high throughput” exploratory in vivo experiments [57], whereas the
HdhQ150 mouse model of HD is more adequate to monitor pre-manifest changes due to its
prolong period leading up to the clinical horizon [14]. The HdhQ150 model also has greater
face validity to identify targets and evaluate interventions due to the slower pathological evolu-
tion [9, 32]. Especially targets, such as astrocytosis or microglia response, can be expected to be
quite different in rapidly versus more slowly evolving neurodegeneration paradigms [61, 62].
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Challenges to establish pre-manifest markers in animal models of HD
The extensive pre-manifest period in HdhQ150 mice provides a unique setting to probe bio-
markers that can be used to monitor the progression of subjects towards the clinical horizon
and potentially serve as surrogates to evaluate pre-symptomatic interventions. MRI here dem-
onstrated measurable differences between HdhQ150 and WT animals. Notably, striatal volume
was reduced even at 8 weeks of age. By 15 weeks of age, motor cortex and striatum were
reduced, with more widespread changes evident at 23 weeks prior to the emergence of behav-
ioral deficits at 36 weeks of age. The onset of behavioral deficits also coincided with a shift from
brain regions not growing, to an actual decline. These subtle changes can be identified in the
HdhQ150 model with disease load being well controlled. In patients, these changes would be
more difficult to identify. Nevertheless, there is evidence that caudate volume is smaller in pre-
manifest patients [63], potentially highlighting the value of the HdhQ150 to further develop
MRI-based biomarkers. Although whole brain atrophy has also been suggested as a pre-mani-
fest measure [64], more defined regional changes, such as in the caudate, might provide earlier
and more specific biomarkers to monitor the disease time course [65].
A major challenge in patients, as in animal models, is the use of longitudinal MRI and to
choose appropriate time points [54]. As it is unknown in patients when the clinical horizon
arises, investigations into the pre-manifest phase are difficult in terms of their timing, as well
as longitudinal follow-up [66]. Most MRI-based biomarker studies therefore rely on cross-sec-
tional images, although a few studies have used longitudinal serial MRI scans [54]. Studies in
transgenic animals provide a level of control that cannot be achieved in patients and can serve
to identify, as well as to validate, MRI-based biomarkers [9, 67]. Being able to perform time-
matched concomitant behavioral analyses further affords an investigation of how low-level
changes in anatomy eventually cumulate into behavioral manifestations, which will be difficult
to achieve in patients considering their heterogeneity and difficulty in predicting a disease
time course. A further advantage of animal studies is the potential to provide histological and
molecular analyses, which are unlikely to be available in pre-manifest patients. The HdhQ150
model provides an extended pre-manifest period that facilitates more extensive studies on this
period. Investigations that go beyond simple structural measures, as used here, should be per-
formed. Ideally, MR spectroscopy and diffusion MRI complement T2-weighted structural
scans, as these can potentially provide more specific markers of tissue changes in the striatum
and cortex [68, 69]. It is important to note though that even in transgenic animals these inves-
tigations are not trivial in terms of logistics and costs, but could provide robustly quantifiable
and validated biomarkers to define the various stages of the condition.
In animal studies commonly the aim is to keep the CAG repeat length consistent across
experimental groups to ensure low variability in outcome measures to increase statistical
power and detect significant effects between groups. This allowed us here to use only ~10 sub-
jects per condition to find significant differences between WT and HdhQ150. However, almost
no correlations between measures survived correction for multiple comparisons, although there
are significant reports in clinical cohorts associating structural MRI changes with behavioral
measures. The key difference here is that the load of CAG repeats in clinical trials is almost
always very variable. This leads to subjects with high and low CAG repeats being included in
the correlation analysis, whereas in our preclinical study the variability of CAG was minimal.
Our correlations here therefore reflect more directly the relationship between MRI measures
and behavior, whereas clinically CAG repeat loading is a significant co-variate (i.e. disease load
effect on measures), which might determine this relationship as a common hidden variable.
Indeed, there is extensive evidence in clinical studies that CAG repeat length is associated with
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brain atrophy and clinical signs [65]. Specifically designed and controlled animal studies (i.e.
low versus high CAG variability) are required to unravel these relationships.
Conclusions
This study performed longitudinal serial MRI scans with concomitant behavioral assess-
ments of motor and cognitive tasks over a 94 week time span in the HdhQ150 knock-in
model of HD. Longitudinal studies of anatomy, as well as behavior, are key to characterize
the phenotype of these animals. We here demonstrated that unlike the R6/2 and R6/1 trans-
genic mouse models, a prolonged pre-manifest period of 36 weeks is present in HdhQ150
animals that affords the identification of MRI-based biomarkers, notably reduced striatal
and cortical volumes. However, there were few significant correlations between outcome
measures potentially indicating that other tissue measures, such as astrocytes, might be
important in the causal cascade between mHTT aggregation and the emergence of behav-
ioral deficits. The HdhQ150 mouse model of Huntington’s disease presents an excellent sys-
tem to identify novel biomarkers, as well as their utility in identifying interventions that act
on the pre-manifest stage of the condition.
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